Home

The Korea Herald

Latest news

Most Popular

  1. 1

    After opposition U-turn, Korea to repeal plan for financial capital gains tax

    After opposition U-turn, Korea to repeal plan for financial capital gains tax
  2. 2

    North Korea fires ballistic missiles hours before US Election Day

    North Korea fires ballistic missiles hours before US Election Day
  3. 3

    Amid record-low approval rating, Yoon forgoes Assembly budget address

    Amid record-low approval rating, Yoon forgoes Assembly budget address
  4. 4

    Gangnam Station ramming suspect to face detention

    Gangnam Station ramming suspect to face detention
  5. 5

    South Korea and Central Asia set stage for first summit

    South Korea and Central Asia set stage for first summit
  1. 6

    Local food festivals enjoy unexpected popularity as snacks go viral

    Local food festivals enjoy unexpected popularity as snacks go viral
  2. 7

    Harris, Trump face off as North Korea tests US on Election Day

    Harris, Trump face off as North Korea tests US on Election Day
  3. 8

    Ruling party leader condemns North Korea troop dispatch as crime against humanity

    Ruling party leader condemns North Korea troop dispatch as crime against humanity
  4. 9

    ‘Children have the right to great stories': Head of Astrid Lindgren Award stands firm against book ban

    ‘Children have the right to great stories': Head of Astrid Lindgren Award stands firm against book ban
  5. 10

    SK chief vows to tackle AI bottleneck along with Nvidia, TSMC

    SK chief vows to tackle AI bottleneck along with Nvidia, TSMC
지나쌤

SK Bioscience logs record high sales

Annual sales reach 929 billion won; operating profits record 474 billion won

By Kan Hyeong-woo

Published : Feb. 7, 2022 - 17:14

    • Link copied

SK Bioscience’s corporate identity (SK Bioscience) SK Bioscience’s corporate identity (SK Bioscience)
SK Bioscience saw record sales of 929 billion won ($774 million) and operating profits of 474 billion won from last year, on the back of strong businesses in its contract manufacturing of the AstraZeneca and Novavax COVID-19 vaccines, the company said Monday.

Compared to 2020 yearly figures, SK Bioscience’s annual sales and operating profits went up by 311 percent and 1,158 percent, respectively.

About half of the annual numbers came in the fourth quarter alone as the company logged 451 billion won in sales and 254 billion won in operating profits during the period.

The biopharmaceutical firm said it will look to continue to build on the growing momentum as it plans to complete the development of its coronavirus vaccine candidate GBP510, secure more vaccine platforms and expand infrastructures this year.

SK Bioscience’s GBP510 is currently undergoing the third and last phase of clinical trials.

More from Headlines